Published: Thu, May 18, 2017
Money | By Armando Alvarado

Insiders Have Increased Positions in: Opko Health, Inc. (NYSE:OPK)

Shares of Opko Health Inc.

Opko Health, Inc. was covered by a number of analysts recently, 1 rated the stock as Buy, 3 rated Outperform, 1 rated Hold, 0 gave an Underperform and 0 rated sell. Opko Health Inc. (NYSE:OPK) has risen 6.00% since April 17, 2017 and is uptrending. Piedmont Investment Advisors LLC acquired a new stake in Opko Health during the third quarter worth approximately $622,000. Formidable Asset Management LLC now owns 11,638 shares of the biotechnology company's stock worth $108,000 after buying an additional 1,096 shares in the last quarter. Comerica Bank purchased a new position in Opko Health during the fourth quarter worth approximately $117,000. During the same period previous year, the business earned ($0.02) earnings per share. Finally, World Asset Management Inc boosted its position in Opko Health by 23.6% in the first quarter. This represents a year-on-year decrease of earning per share of $-0.04 from corresponding quarter of last year.

Opko Health Inc (NASDAQ:OPK)'s revenue estimates for the current quarter are $323.42 Million according to 5 number of analysts, for the current quarter the company has high revenue estimates of $336.1 Million in contradiction of low revenue estimates of $317 Million. (NASDAQ:OPK) traded down 2.94% during midday trading on Tuesday, hitting $6.60. During the last month, the stock has changed -10.76% and performed -27.51% over the last 6 months.

The blending and weighting of numbers above created the technical model built by Capital Market Laboratories ( The stock closing price is now trading downward to its 50 day moving average with change of -33.84%, tumbled to its 20 day moving average with figure of -17.51% and behind its 200 day moving average with value -28.09%.

CREDIT SUISSE: The WannaCry ransomware attack could give Microsoft's stock a boost
A global ransomware attack wormed its way onto the computers of hospitals‚ companies‚ state agencies and individuals this weekend. Failure to pay would leave the data scrambled and likely beyond fix unless users had unaffected backup copies.

Opko Health, Inc. (OPK) has an Average Brokerage Recommendation (ABR) of 1.4, according to data compiled by Zacks Investment Research. The Psagot Investment House Ltd holds 22,818 shares with $212,000 value, down from 284,039 last quarter. The firm had revenue of $296.10 million during the quarter, compared to the consensus estimate of $313.36 million. Opko Health reported earnings per share of $0.02 during the same quarter last year, which would suggest a negative year over year growth rate of 350%. For the next year, analysts expect that the business will post earnings of ($0.03) per share, with EPS estimates ranging from ($0.17) to $0.10. Opko Health, Inc. (OPK) 52 week low value is at $6.65 and its current distance from 52 week low value is -0.75%.

Receive News & Ratings for Opko Health Inc. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & worldwide trademark & copyright laws. The original version of this story can be accessed at OPK has been the subject of several recent research reports. Standpoint Research reiterated a "buy" rating and set a $14.00 target price on shares of Opko Health in a report on Sunday, March 5th. Guggenheim initiated coverage on shares of Opko Health in a research note on Tuesday, March 14th. Jefferies Group LLC cut their price target on shares of Opko Health from $10.00 to $8.00 and set a "hold" rating on the stock in a report on Thursday, March 2nd. They set a "buy" rating and a $25.00 target price on the stock. Meanwhile, due to a recent pullback which led to a fall of nearly -11.53% in the past one month, the stock price is now with underperforming -29.03% so far on the year - still in weak zone. Opko Health now has a consensus rating of "Hold" and a consensus target price of $15.64. A total of 6.55 million shares exchanged at hands and its average trading volume is standing at 4.51 million shares. Following the completion of the acquisition, the insider now owns 24,763,133 shares in the company, valued at approximately $171,608,511.69.

In related news, CEO Phillip Md Et Al Frost acquired 3,600 shares of the firm's stock in a transaction that occurred on Tuesday, February 21st. Beta value of the stock is marked at 1.83. The disclosure for this purchase can be found here. Its share price has decline -12.53% in three months and is down -4.26% for the last five trades.

Heading into the stock price potential, Opko Health, Inc. needs to grow just 134.85% to cross its median price target of $15.5.

Like this: